Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.
about
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesStructural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based ImmunogensLongitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodiesNeutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from IndiaAnti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypesAppreciating HIV type 1 diversity: subtype differences in Env.Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopesLimited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models.The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8.Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation.Specificity of the autologous neutralizing antibody responseA single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop.Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trialFactors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies.Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infectionAnti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and PotencyIntraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer.Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection.In silico Analysis of HIV-1 Env-gp120 Reveals Structural Bases for Viral Adaptation in Growth-Restrictive Cells.Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.Synergism between a CD4-mimic peptide and antibodies elicited by a constrained V3 peptide.Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma.Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regionsHigh titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.Limitations to the structure-based design of HIV-1 vaccine immunogens.
P2860
Q27489000-2B1B6389-E9E3-4ACF-8192-FBB85C3EC085Q27658173-E92F04CA-2DA1-4B34-838A-ABA0A654CCEBQ28477253-B587A21A-C0E9-41A1-ACD8-4E212C1CECCFQ28483205-8214A7D9-52B0-41D1-8F08-BD3D1CD87F7FQ28752503-F8118911-6AB9-4736-ACE7-A24812B742A0Q30375834-776C0AD0-D0A0-41F2-85DA-C284296DFF0FQ30603475-F8A66997-6517-4F5D-92B8-49C327966CBCQ30994182-385B6E96-E769-449E-B26D-E6B4F5746DBDQ33504604-BA532D1E-1AF1-4F76-A579-73B4F1D9815DQ33526340-1D90CCB1-7892-4A90-A29E-BC9E75E78287Q33640144-8F703292-9CC6-42EA-978A-B3673BFA16E8Q34017550-E8BE07C3-6520-4408-BAC1-C91FBCFFCEEBQ34128200-75B1B555-FDDD-4218-A6BC-3B7588748A10Q34309493-97354645-126B-43D5-A417-5464175DCA3BQ34415389-46E8EB9E-0B24-417C-9BC8-C4B47EDC20FFQ34463861-A07080CA-A1FA-47D2-B3E5-BE4D5FB48A5EQ34543052-A7B57C0C-E1CD-40A8-A2B3-4E0D5332DCABQ34562259-3F0E777A-22C9-4AE3-9ECB-0F77E6CE087AQ34717733-4FE636BB-E271-41C6-A2BB-EA366F4C41FAQ35102328-856E7D82-9FE4-4229-826B-8BA054A83572Q35122067-F9BEEBEB-25A9-4C77-897B-95D6A8E29841Q35635163-17429BF5-992B-4DA7-B106-CAFC06C2C8FBQ35641369-ED047976-8143-4EF5-87E5-96E4D45F0483Q35647772-3E49FE63-E51C-4F37-8E6F-90241C258940Q35785244-71A1C182-E656-4A80-96FB-C71E9D38A697Q35857221-1C590FA9-E753-4903-9736-7E3CBEA0951AQ35857683-FCDF7DA9-6567-48B7-BD7F-AD9CF9042F51Q36384117-2B4D0CBF-D3DF-4860-9646-CE69FBC715F1Q36483346-D2195DA7-C67B-45F8-AB13-322E0C770707Q36558933-031826CE-01AB-47A3-861E-6F10BA363715Q36600380-62E78986-74F7-4080-BA54-81C26B14579FQ36673173-1112D3BC-1543-48EF-B887-45FF5C66946AQ36715717-7E2C8C24-3B61-40D8-A475-778B7E602FB7Q36974754-DA1BDB3B-B4ED-42BB-A43E-87B3060A3B89Q37051645-C2397B63-6977-45D0-889D-5EEFFC455086Q37084521-6BC225C9-091F-48E2-BFD8-F192EAE36EFDQ37099851-3E6CE042-FD07-4AC6-A82F-15701D1E6095Q37471315-7745E150-DF5E-46CA-AD67-6AC87E3CFEFAQ37554149-F20EAECE-E24A-41A6-A1B7-2F2D129D237EQ37910841-A69D8986-3ECA-4E0C-8930-5E1DDC6102B3
P2860
Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2005
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antibodies that are cross-reac ...... restricted by epitope masking.
@en
Antibodies that are cross-reac ...... restricted by epitope masking.
@nl
type
label
Antibodies that are cross-reac ...... restricted by epitope masking.
@en
Antibodies that are cross-reac ...... restricted by epitope masking.
@nl
prefLabel
Antibodies that are cross-reac ...... restricted by epitope masking.
@en
Antibodies that are cross-reac ...... restricted by epitope masking.
@nl
P2093
P2860
P921
P1433
P1476
Antibodies that are cross-reac ...... restricted by epitope masking.
@en
P2093
Abraham Pinter
Chavdar Krachmarov
Miroslaw K Gorny
Phillipe N Nyambi
Samuel C Kayman
Susan Zolla-Pazner
William J Honnen
P2860
P304
P356
10.1128/JVI.79.2.780-790.2005
P407
P577
2005-01-01T00:00:00Z